THE IMPACT OF METABOLIC DYSFUNCTION ON THE COURSE AND FIBROGENESIS IN CHRONIC HEPATITIS B (Literature Review)

Authors

  • B. M. Tadjiev Tashkent State Medical University, Tashkent, Republic of Uzbekistan Author
  • G. A. Mirzaeva Tashkent State Medical University, Tashkent, Republic of Uzbekistan Author

Keywords:

Keywords: chronic hepatitis B; metabolic dysfunction-associated steatotic liver disease; fibrogenesis; gut microbiota; liver cirrhosis; gut–liver axis.

Abstract

Background. Given the rising global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), its impact on the natural course of chronic hepatitis B (CHB) has become an issue of growing clinical relevance; comorbidity rates range from 14% to 70% across cohorts. This review summarizes current data on the pathogenetic mechanisms linking HBV infection and metabolic dysfunction, the role of the gut microbiota and gut–liver axis in liver fibrogenesis, and the clinical outcomes of this comorbidity, including the risk of cirrhosis, hepatocellular carcinoma (HCC), and cardiovascular events. The relationship between steatosis and viral replication appears bidirectional and context-dependent: hepatic steatosis may suppress HBsAg secretion and HBV replication, while concurrent metabolic dysfunction can accelerate fibrogenesis through chronic inflammation, oxidative stress, and gut dysbiosis. The potential of microbiome- and metabolome-based biomarkers for disease monitoring is discussed, along with unresolved questions warranting further study, including in cohorts with HBV/HDV coinfection.

References

1.Lv D., Han N., Liu H., Tang H. Hepatitis B Virus-Related Liver Disease and Gut Microbiota: An Updated Review // Microorganisms. – 2025. – Vol. 13, № 11. – Art. 2445. – DOI: 10.3390/microorganisms13112445.

2.Majeed A.A., Butt A.S. Hepatitis B virus infection and metabolic dysfunction associated steatotic liver disease: Rising pandemic with complex interaction // World Journal of Hepatology. – 2025. – Vol. 17, № 1. – Art. 100968. – DOI: 10.4254/wjh.v17.i1.100968.

3.Distinct gut microbiota and metabolomic profiles in HBV-related liver cirrhosis: insights into disease progression / K. Shi, L. Sun, Y. Feng, X. Wang // Frontiers in Cellular and Infection Microbiology. – 2025. – Vol. 15. – Art. 1560564. – DOI: 10.3389/fcimb.2025.1560564.

4.Gut microbiota and metabolite profiles in HBV cirrhosis with persistent liver enzyme abnormalities / H. He, R. Zou, X. Liao, Y. Lan // Frontiers in Microbiology. – 2025. – Vol. 16. – Art. 1645023. – DOI: 10.3389/fmicb.2025.1645023.

5.Clinical and epidemiological characteristics of chronic hepatitis C in the Tyva Republic / A.A. Saryglar, S.O. Dongak, A.D. Ibrokhimova, K.E. Novak, E.V. Esaulenko // Journal of Infectology. – 2023. – Vol. 15, № 1. – P. 55–60. – DOI: 10.22625/2072-6732-2023-15-1-55-60.

6.Metabolic dysfunction-associated steatotic liver disease in chronic hepatitis B patients: risks of severe liver disease and cardiovascular disease / N. Zhang, Z. Xu, F. Lin, H. Fan, D. Zhou, S. Zheng, P. Jin, H. Gu, C. Yu, L. Jiang // Frontiers in Cellular and Infection Microbiology. – 2026. – Vol. 16. – Art. 1806927. – DOI: 10.3389/fcimb.2026.1806927.

7.Liu Q., Mu M., Chen H., Zhang G., Yang Y., Chu J., Li Y., Yang F., Lin S. Hepatocyte steatosis inhibits hepatitis B virus secretion via induction of endoplasmic reticulum stress // Molecular and Cellular Biochemistry. – 2022. – Vol. 477, № 11. – P. 2481–2491. – DOI: 10.1007/s11010-021-04143-z.

8.Zheng Q., Zou B., Wu Y., Yeo Y., Wu H., Stave C.D., Cheung R.C., Nguyen M.H. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B // Alimentary Pharmacology & Therapeutics. – 2021. – Vol. 54, № 9. – P. 1100–1109. – DOI: 10.1111/apt.16595.

9.Yoon S., Jung J., Kim T., Park S., Chwae Y.J., Shin H.J., Kim K. Adiponectin, a downstream target gene of peroxisome proliferator-activated receptor γ, controls hepatitis B virus replication // Virology. – 2011. – Vol. 409, № 2. – P. 290–298. – DOI: 10.1016/j.virol.2010.10.024.

10.Van Herck M.A., Weyler J., Kwanten W.J., Dirinck E.L., De Winter B.Y., Francque S.M., Vonghia L. The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity // Frontiers in Immunology. – 2019. – Vol. 10. – Art. 82. – DOI: 10.3389/fimmu.2019.00082.

11.Dapito D.H., Mencin A., Gwak G.Y., Pradere J.P., Jang M.K., Mederacke I., Caviglia J.M., Khiabanian H., Adeyemi A., Bataller R. [et al.] Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4 // Cancer Cell. – 2012. – Vol. 21, № 4. – P. 504–516.

Downloads

Published

2026-09-18